Page last updated: 2024-11-04

haloxazolam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

haloxazolam: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3563
CHEMBL ID2104461
CHEBI ID31666
SCHEMBL ID156227
MeSH IDM0070682

Synonyms (35)

Synonym
haloxazolam
oxazolo[3,2-d](1,4)benzodiazepin-6(5h)-one, 2,3,7,11b-tetrahydro-10-bromo-11b-(2-fluorophenyl)-
cs-430
somelin
oxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one, 2,3,7,11b-tetrahydro-10-bromo-11b-(2-fluorophenyl)-
cs 430
10-bromo-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one
haloxazolam [inn:jan]
brn 0569670
haloxazolamum [inn-latin]
dea no. 2771
10-bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one
DB01476
D01758
59128-97-1
somelin (tn)
haloxazolam (jp17/inn)
10-bromo-11b-(2-fluorophenyl)-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one
haloxazolamum
m448l2v8xp ,
unii-m448l2v8xp
haloxazolam [who-dd]
haloxazolam [inn]
haloxazolam [mart.]
haloxazolam [mi]
haloxazolam [jan]
CHEMBL2104461
SCHEMBL156227
10-bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6(5h)-one #
10-bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo[3,2-d](1,4)benzodiazepin-6(5h)-one
10-bromo-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo[3,2-d][1,4]benzodiazepin-6(5h)-one
XDKCGKQHVBOOHC-UHFFFAOYSA-N
CHEBI:31666
Q4345875
DTXSID60866740

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (37.50)18.7374
1990's4 (50.00)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]